Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study

医学 腹腔疾病 安慰剂 内科学 临床终点 胃肠病学 人口 不利影响 绒毛萎缩 面筋 临床试验 疾病 病理 环境卫生 替代医学
作者
Marja‐Leena Lähdeaho,Mika Scheinin,Pekka Vuotikka,Juha Taavela,Alina Popp,Johanna Laukkarinen,Jukka Koffert,Olli‐Pekka Koivurova,Marko Pesu,Laura Kivelä,Zsófia Lovró,Joni Keisala,Jorma Isola,Jane R. Parnes,Francisco León,Markku Mäki
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (12): 948-959 被引量:74
标识
DOI:10.1016/s2468-1253(19)30264-x
摘要

Background Interleukin 15 (IL-15) is implicated in the pathophysiology of coeliac disease. AMG 714 is the first anti-IL-15 monoclonal antibody to be investigated for the treatment of coeliac disease. We aimed to investigate the effects of AMG 714 in patients with coeliac disease who underwent gluten challenge. Methods This randomised, double-blind, placebo-controlled, parallel-group, phase 2a trial was done at three clinical sites in Finland. Inclusion criteria included age 18–80 years, a confirmed diagnosis of coeliac disease, and adherence to a gluten-free diet for at least 12 months before screening. Patients were randomly assigned (1:1:1) to 150 mg AMG 714, 300 mg AMG 714, or placebo using permuted blocks and stratified by study site and sex. Patients and study staff were masked to treatment assignment. Treatments were administered by two subcutaneous injections every 2 weeks for 10 weeks (total six doses). Patients without severe villous atrophy at baseline received a gluten challenge (2–4 g daily) during weeks 2–12. Small bowel biopsy samples were obtained for histological assessments at baseline and week 12. The primary efficacy endpoint was the percentage change from baseline to week 12 in villous height-to-crypt depth (VHCD) ratio. Secondary endpoints were CD3-positive intraepithelial lymphocyte density; clinical symptoms measured by gastrointestinal symptom rating scale (GSRS), coeliac disease GSRS, and Bristol stool form scale (BSFS); and changes in anti-tTG and anti-DGP antibodies from baseline. The primary analysis was done in the per-protocol 1 population of patients who received at least one dose of study drug and who underwent the gluten challenge. Safety analyses were done in all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, NCT02637141 and EudraCT, 2015-003647-19. Findings Between April 13, 2016, and Nov 22, 2016, 64 patients were enrolled and randomly assigned to either the 150 mg AMG 714 group (n=22), the 300 mg AMG 714 group (n=22), or the placebo group (n=20). Two patients did not start treatment and two did not provide post-treatment biopsy samples. 49 patients underwent the gluten challenge (per-protocol 1 population) and 11 patients did not because of baseline villous atrophy. AMG 714 did not prevent mucosal injury due to gluten challenge. The least square mean difference in the relative change from baseline in VHCD ratio was −2·49% (95% CI −16·82 to 11·83; p=0·73) between 150 mg AMG 714 and placebo and 6·39% (−7·07 to 19·85; p=0·34) between 300 mg AMG 714 and placebo. Neither comparison was statistically significant. The density of CD3-positive intraepithelial lymphocytes increased in all groups, with smaller increases in the 300 mg group (−41·24% [95% CI −79·28 to −3·20] vs placebo, nominal p=0·03) but not the 150 mg group (−14·32% [–54·39 to 25·74], nominal p=0·47). Clinical symptoms were ameliorated with AMG 714 treatment between baseline and week 12, particularly diarrhoea as measured by the BSFS (nominal p=0·01 for 150 mg vs placebo, and nominal p=0·0002 for 300 mg vs placebo). Serum antibody titres for anti-tTG and anti-DGP antibodies increased in all three treatment groups, with no significant difference between AMG 714 and placebo. Treatment-emergent adverse events occurred in 21 (95%) patients in the 150 mg AMG 714 group, 0 (95%) in the 300 mg AMG 714 group, and 19 (100%) in the placebo group. The most common treatment-emergent adverse events were gastrointestinal disorders (17 [77%] participants in the 150 mg AMG 714 group, 16 [76%] in the 300 mg AMG 714 group, and 13 [68%] in the placebo group). Injection site reactions were the most common individual adverse event, reported in eight (36%) patients in the 150 mg AMG 714 group, 11 (52%) in the 300 mg group, and five (26%) in the placebo group. No serious adverse events occurred. Interpretation The primary endpoint, change in VHCD ratio from baseline after 12 weeks of treatment in patients with coeliac disease undergoing gluten challenge, was not significantly different between placebo and AMG 714 at either 150 mg or 300 mg. Effects on intraepithelial lymphocyte density and symptoms suggest that further research of AMG 714 may be warranted in patients with non-responsive coeliac disease. Funding Celimmune and Amgen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Tina酱完成签到 ,获得积分10
刚刚
琪琪完成签到,获得积分10
刚刚
双碳小王子完成签到,获得积分10
2秒前
smottom应助科研通管家采纳,获得10
4秒前
4秒前
明时完成签到,获得积分10
5秒前
杨瑞东完成签到 ,获得积分10
8秒前
yyyy完成签到,获得积分10
16秒前
缥缈的平卉完成签到 ,获得积分10
17秒前
量子星尘发布了新的文献求助10
28秒前
李爱国应助大橙子采纳,获得10
29秒前
magictoo发布了新的文献求助30
35秒前
37秒前
yang完成签到,获得积分10
37秒前
Minicoper发布了新的文献求助10
38秒前
快乐丸子完成签到,获得积分10
39秒前
简单而复杂完成签到,获得积分10
39秒前
大橙子发布了新的文献求助10
43秒前
张牧之完成签到 ,获得积分10
45秒前
冷冷暴力完成签到,获得积分10
47秒前
YYY完成签到,获得积分10
47秒前
47秒前
gujian完成签到 ,获得积分10
50秒前
帅气的秘密完成签到 ,获得积分10
51秒前
自然函发布了新的文献求助10
55秒前
冰冰双双完成签到,获得积分10
55秒前
开心夏旋完成签到 ,获得积分0
57秒前
我要读博士完成签到 ,获得积分10
1分钟前
活泼的大船完成签到,获得积分10
1分钟前
AFF完成签到,获得积分10
1分钟前
1分钟前
无私小小完成签到,获得积分10
1分钟前
随心所欲完成签到 ,获得积分10
1分钟前
润润轩轩完成签到 ,获得积分10
1分钟前
CodeCraft应助大橙子采纳,获得10
1分钟前
ZR完成签到,获得积分10
1分钟前
magictoo完成签到,获得积分10
1分钟前
陈昊发布了新的文献求助10
1分钟前
zhangliangfu完成签到 ,获得积分10
1分钟前
金石为开完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022